Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Crohns Disease for at least 6 weeks~* Moderate to severe disease activity (CDAI \>= 220 and \<=450)~* No history of azathioprine, 6-MP (6 Mercaptopurine), or biologic treatments~* Are either: Corticosteriod-dependent, OR considered for a 2nd (or greater) course of corticosteriod, OR 5-ASA failures, Or Budesonide failures~Exclusion Criteria:~* History of abdominal surgery within the last 6 months~* Have an ostomy or stoma \[An operation to create an opening from an area inside the body to the outside\]~* Are pregnant, nursing, or planning pregnancy (both men and women)~* Serious simultaneous illness that could interfere with study participation~* Use of any investigational drug within 30 days~* Have a concomitant diagnosis or any history of congestive heart failure~* Weigh more than 140 kilograms (or 310 pounds)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 003 (Type: EXPERIMENTAL): infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
- 001 (Type: EXPERIMENTAL): infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
- 002 (Type: EXPERIMENTAL): infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).